Archives

by in
Entry Author Date Location
Well-Traveled Rhodes Leaves Epizyme For Atlas Venture Partnership 09/29/14 Boston
Sold For Parts, Accelerator Grad Allozyne Reaches End of the Line 09/18/14 Seattle
FDA OKs Astute Medical’s First Diagnostic for Acute Kidney Injury 09/08/14 San Diego
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief 09/07/14 Boston
East Coast Biotech Roundup: Biogen, Civitas, Rhythm, Alkermes, & More 08/29/14 Boston
To Take On New York, Accelerator Makes Big Changes 08/14/14 New York
With $22M, True North Points Toward Rare-Disease Clinical Trials 06/17/14 San Francisco
Radius Health Recharges IPO After Two Week Hiatus 05/21/14 Boston
With Novartis Deal Dead, Proteon Embarks on Plan B With $45M Round 05/16/14 Boston
East Coast Biotech Roundup: Mergers, Rhythm, Regeneron, & More 05/09/14 Boston
Rhythm Eyes Pivotal Study as GI Drug for Diabetics Hits Phase 2 Mark 05/06/14 Boston
Seeking Tau: BMS Buys iPierian and Brain-Disease Program for $175M 04/29/14 San Francisco
Syndax Plots $69M IPO For Cancer Drug’s Stretch Run 03/27/14 Boston
Proteon, Looking Past Ill-Fated Novartis Deal, Goes it Alone 03/18/14 Boston
Revamped Radius Health Looks to Cash In With $86M IPO 02/27/14 Boston
East Coast Biotech Roundup: HART, CoStim, Forest/Actavis, & More 02/21/14 Boston
Immuno-Oncology Fever Rages as Novartis Snaps Up CoStim 02/18/14 Boston
Radius Health Churns Through 3 CEOs, as Osteoporosis Drug Delayed 12/20/13 Boston
Trivascular Obtains $40,000,000 Series E Funding Round 11/18/13 San Francisco
East Coast Biotech Roundup: Pronutria, Alzheon, Nextcode, & More 10/25/13 Boston
Sideris Pharmaceuticals Receives $32,000,000 Series A Funding 10/23/13 Boston
Mitokyne Garners $45,000,000 Series A Financing Round 10/21/13 Boston
East Coast Life Sciences Roundup: Verdine, Ariad, Karyopharm, & More 10/11/13 Boston
iPierian Receives $30,000,000 New Funding Round 09/04/13 San Francisco
True North Therapeutics Garners Series A Funding 09/04/13 San Francisco
East Coast Life Sciences Roundup: Syndax, Enteris, Invivo, & More 08/30/13 Boston
Syndax Pockets $26.6M For Final Stage Push With Cancer Drug 08/27/13 Boston
Syndax Pharmaceuticals Lands $26,600,000 Series B Financing 08/27/13 Boston
VLST, After Nine Years and $50M, Sells Assets and Winds Down 08/07/13 Seattle
San Diego’s Conatus Pharmaceuticals Sets Price Range for IPO Shares 07/09/13 San Diego
Page 1 of 8 next page »